## Inotuzumab ozogamicin, an anti-CD22–calecheamicin relapsed acute lymphocytic leukaemia: a phase 2 study

Lancet Oncology, The 13, 403-411 DOI: 10.1016/s1470-2045(11)70386-2

**Citation Report** 

#	ARTICLE	IF	CITATIONS
1	CD19 as an attractive target for antibody-based therapy. MAbs, 2012, 4, 571-577.	5.2	73
2	The future role of monoclonal antibody therapy in childhood acute leukaemias. British Journal of Haematology, 2012, 159, 3-17.	2.5	20
3	Anti-CD22 therapy in acute lymphoblastic leukaemia. Lancet Oncology, The, 2012, 13, 329-331.	10.7	11
4	Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1819-1826.	2.0	43
5	Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 3876-3883.	1.6	77
6	Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. Leukemia Research, 2012, 36, 1517-1520.	0.8	13
7	Novel CD20 monoclonal antibodies for lymphoma therapy. Journal of Hematology and Oncology, 2012, 5, 64.	17.0	116
8	Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice. International Journal of Molecular Sciences, 2012, 13, 16020-16045.	4.1	40
9	Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?. Hematology American Society of Hematology Education Program, 2012, 2012, 129-136.	2.5	74
10	Using antibodies to target cancer therapeutics. Expert Opinion on Biological Therapy, 2012, 12, 1173-1190.	3.1	19
11	The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnology, 2012, 30, 631-637.	17.5	637
12	Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook. BioDrugs, 2013, 27, 293-304.	4.6	69
14	Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review. Methods in Molecular Biology, 2013, 1045, 1-27.	0.9	127
15	Antibody–Drug Conjugate Payloads. Methods in Molecular Biology, 2013, 1045, 51-70.	0.9	55
16	Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncology, The, 2013, 14, e205-e217.	10.7	338
17	On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 557-571.	1.8	67
18	Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates. Expert Review of Clinical Pharmacology, 2013, 6, 541-555.	3.1	26
20	A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Seminars in Hematology, 2013, 50, 185-196.	3.4	264

ATION RE

#	Article	IF	CITATIONS
21	Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer. Radiotherapy and Oncology, 2013, 108, 331-336.	0.6	46
22	Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. British Journal of Surgery, 2013, 100, 1377-1387.	0.3	317
23	Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1059-1064.	2.0	65
24	Novel agents and biomarkers for acute lymphoid leukemia. Journal of Hematology and Oncology, 2013, 6, 40.	17.0	26
25	Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 296-301.	0.4	50
26	Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncology, 2013, 9, 69-91.	2.4	26
27	PrzeciwciaÅ,a monoklonalne w leczeniu ostrych biaÅ,aczek limfoblastycznych. Acta Haematologica Polonica, 2013, 44, 208-214.	0.3	0
28	Antibody-Drug Conjugates in Cancer Therapy. Annual Review of Medicine, 2013, 64, 15-29.	12.2	649
29	CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 307-314.	0.4	31
30	Acute lymphoblastic leukaemia. Lancet, The, 2013, 381, 1943-1955.	13.7	879
31	CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Science Translational Medicine, 2013, 5, 177ra38.	12.4	1,748
32	Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies. Current Hematologic Malignancy Reports, 2013, 8, 123-131.	2.3	18
33	The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Natural Product Reports, 2013, 30, 625.	10.3	93
34	Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions. Drugs, 2013, 73, 439-461.	10.9	10
35	Drugâ€conjugated antibodies for the treatment of cancer. British Journal of Clinical Pharmacology, 2013, 76, 248-262.	2.4	126
36	Monoclonal antibody-based therapies in cancer: Advances and challenges. , 2013, 138, 452-469.		96
37	CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia. Cancer, 2013, 119, 2671-2674.	4.1	3
38	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer, 2013, 119, 2728-2736.	4.1	265

#	Article	IF	CITATIONS
39	Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opinion on Biological Therapy, 2013, 13, 269-282.	3.1	22
40	Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leukemia and Lymphoma, 2013, 54, 2592-2600.	1.3	13
41	Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leukemia and Lymphoma, 2013, 54, 21-27.	1.3	32
42	Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplantation, 2013, 48, 666-670.	2.4	50
43	New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors. Hematology American Society of Hematology Education Program, 2013, 2013, 131-137.	2.5	15
44	Novel treatment options for acute myelocytic leukemia. Clinical Investigation, 2013, 3, 979-990.	0.0	Ο
45	Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives. Frontiers in Oncology, 2013, 3, 106.	2.8	5
46	Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches. Current Opinion in Oncology, 2013, 25, 707-715.	2.4	20
47	Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Current Opinion in Oncology, 2013, 25, 701-706.	2.4	24
48	Antibody–drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. Future Oncology, 2013, 9, 355-368.	2.4	27
50	Survival Outcome of Local Excision versus Radical Resection of Colon or Rectal Carcinoma. Annals of Surgery, 2013, 258, 563-571.	4.2	91
51	A hyperactive postprandial response in the neorectum â^' the clue to low anterior resection syndrome after total mesorectal excision surgery?. Colorectal Disease, 2013, 15, e599-606.	1.4	46
52	Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatricâ€based protocol. British Journal of Haematology, 2013, 163, 458-464.	2.5	27
53	Administration of alemtuzumab and <scp>G</scp> â€ <scp>CSF</scp> to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase <scp>II</scp> study. European Journal of Haematology, 2013, 91, 315-321.	2.2	28
54	Trial watch. Oncolmmunology, 2013, 2, e22789.	4.6	92
55	Treating adults with acute lymphoblastic leukemia: it is time to grow up. International Journal of Hematologic Oncology, 2013, 2, 5-8.	1.6	0
56	How I treat older patients with ALL. Blood, 2013, 122, 1366-1375.	1.4	86
57	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica, 2013, 98, 945-952.	3.5	54

#	Article	IF	CITATIONS
58	Acute lymphoblastic leukemia in adolescents and young adults – from genomics to the clinics. Clinical Oncology in Adolescents and Young Adults, 2013, , 49.	0.8	3
59	Identification and Validation of Targets for Cancer Immunotherapy: From the Bench-to-Bedside. , 0, , .		0
60	Immunotherapy for Pediatric Leukemia. Frontiers in Oncology, 2013, 3, 166.	2.8	10
61	Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology. Oncotarget, 2013, 4, 397-412.	1.8	40
62	Inotuzumab Ozogamicin in the treatment of acute lymphoblastic leukemia. Frontiers in Bioscience - Elite, 2014, E6, 40-45.	1.8	13
64	Antibody–Drug Conjugates Delivering DNA Cytotoxics. , 2014, , 479-490.		1
65	Novel methods and approaches to acute lymphoblastic leukemia drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 1435-1446.	5.0	8
66	Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development. Future Oncology, 2014, 10, 2201-2212.	2.4	7
67	Antibody Therapy for Pediatric Leukemia. Frontiers in Oncology, 2014, 4, 82.	2.8	17
68	Childhood and Adolescent B-Cell Lymphoma: Bench to Bedside and Back to Bench. , 2014, , 247-285.		Ο
69	Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncology, 2014, 10, 1659-1678.	2.4	11
70	Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 4134-4140.	1.6	577
71	Will novel agents for ALL finally change the natural history?. Best Practice and Research in Clinical Haematology, 2014, 27, 247-258.	1.7	7
72	Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research, 2014, 38, 1441-1445.	0.8	11
73	Humoral and Cellular Immunotherapy in ALL inÂChildren, Adolescents, and Young Adults. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S6-S13.	0.4	8
74	Invited Comment on G. Bassotti and E. Battaglia: Postoperative colonic motility after transverse loop colostomy: a further tassel in the mosaic. Techniques in Coloproctology, 2014, 18, 1087-1088.	1.8	0
75	Low Anterior Resection Syndrome and Quality of Life. Diseases of the Colon and Rectum, 2014, 57, 585-591.	1.3	238
76	Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons and the American Society of Colorectal Surgeons Evidence Based Reviews in Surgery – Colorectal Surgery. Diseases of the Colon and Rectum, 2014, 57, 806-8 <u>09</u> .	1.3	0

#	Article	IF	CITATIONS
77	Treatment of Fecal Incontinence in the Era of Neuromodulation. Diseases of the Colon and Rectum, 2014, 57, 1143-1144.	1.3	0
78	Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 0, , 1.	2.7	3
79	Emerging new anticancer biological therapies in 2013 (haematological malignancies). Current Opinion in Oncology, 2014, 26, 363-370.	2.4	5
80	Commentary on Sajid <i>et al</i> Colorectal Disease, 2014, 16, 15-16.	1.4	2
81	Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2014, 61, 369-372.	1.5	54
82	CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leukemia and Lymphoma, 2014, 55, 624-627.	1.3	35
83	Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy. Angewandte Chemie - International Edition, 2014, 53, 3796-3827.	13.8	779
84	Transanal endoscopic microsurgery. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 143-157.	2.4	16
85	Sphincter-Sparing Surgery in Patients with Low-Lying Rectal Cancer: Techniques, Oncologic Outcomes, and Functional Results. Journal of Gastrointestinal Surgery, 2014, 18, 1358-1372.	1.7	57
86	Novel targeted therapies in acute lymphoblastic leukemia. Leukemia and Lymphoma, 2014, 55, 737-748.	1.3	35
87	Hematopoietic Cell Transplantation in Children with Cancer. Pediatric Oncology, 2014, , .	0.5	3
88	Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs, 2014, 23, 911-924.	4.1	17
89	The Next Generation of Antibody Drug Conjugates. Seminars in Oncology, 2014, 41, 637-652.	2.2	53
91	Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. Leukemia and Lymphoma, 2014, 55, 1715-1724.	1.3	22
92	Functional results after treatment for rectal cancer. Journal of Coloproctology, 2014, 34, 055-061.	0.1	20
93	Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas. Chemical Science, 2014, 5, 2398.	7.4	86
94	Emerging drugs for acute lymphocytic leukemia. Expert Opinion on Emerging Drugs, 2014, 19, 37-50.	2.4	4
95	Novel Antibody Therapy in Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2014, 9, 165-173.	2.3	9

#	Article	IF	CITATIONS
96	Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen. Leukemia Research, 2014, 38, 532-536.	0.8	6
97	Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia Research, 2014, 38, 564-568.	0.8	10
98	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology, 2014, 165, 504-509.	2.5	73
99	Advances in the treatment of hematologic malignancies using immunoconjugates. Blood, 2014, 123, 2293-2301.	1.4	39
101	The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2015, 2015, 400-405.	2.5	16
102	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a <scp>CD</scp> 22 monoclonal antibody. American Journal of Hematology, 2015, 90, 193-196.	4.1	35
104	Acute Lymphoblastic Leukemia, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1240-1279.	4.9	116
105	New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer, 2015, 121, 2517-2528.	4.1	200
106	Toward effective targeted therapy for the treatment of adult acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2015, 4, 1-4.	1.6	0
107	The Challenges of Managing Older Patients with Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e343-e351.	3.8	9
108	A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells. Journal of Immunology Research, 2015, 2015, 1-14.	2.2	19
109	Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-7.	2.2	15
111	Local Excision for Early Stage Rectal Cancer in Patients Over Age 65 Years. Diseases of the Colon and Rectum, 2015, 58, 172-178.	1.3	10
112	Monoclonal antibodies in acute lymphoblastic leukemia. Blood, 2015, 125, 4010-4016.	1.4	144
113	Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opinion on Biological Therapy, 2015, 15, 895-908.	3.1	25
114	Novel approaches to pediatric leukemia treatment. Expert Review of Anticancer Therapy, 2015, 15, 811-828.	2.4	2
115	Personalized medicine in adult acute lymphoblastic leukemia. Haematologica, 2015, 100, 855-858.	3.5	19
116	The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Therapeutic Advances in Hematology, 2015, 6, 253-261.	2.5	25

#	Article	IF	CITATIONS
117	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2015, 16, 57-66.	10.7	1,031
118	Novel agents for the treatment of childhood acute leukemia. Therapeutic Advances in Hematology, 2015, 6, 61-79.	2.5	49
119	Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody. MAbs, 2015, 7, 66-76.	5.2	3
120	Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a populationâ€based crossâ€sectional study. Colorectal Disease, 2015, 17, 26-37.	1.4	114
121	CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia, 2015, 29, 1637-1647.	7.2	343
122	What Are the Best Questionnaires To Capture Anorectal Function After Surgery in Rectal Cancer?. Current Colorectal Cancer Reports, 2015, 11, 37-43.	0.5	68
123	Antibody Drug Conjugates: Preclinical Considerations. AAPS Journal, 2015, 17, 525-534.	4.4	41
125	MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015001.	1.3	7
126	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematology,the, 2015, 2, e108-e117.	4.6	36
127	Reduced luminal circumference of tumors plays a key role in anorectal function during the early period after neoadjuvant chemoradiation therapy in rectal cancer patients. International Journal of Colorectal Disease, 2015, 30, 465-474.	2.2	0
129	A longitudinal study of gender differences in quality of life among Japanese patients with lower rectal cancer treated with sphincter-saving surgery: a 1-year follow-up. World Journal of Surgical Oncology, 2015, 13, 91.	1.9	13
130	Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Molecular Immunology, 2015, 67, 107-116.	2.2	129
131	Immunopathology and Immunotherapy of Lymphoblastic Leukaemia. , 2015, , 105-116.		0
132	Future of Therapy in Acute Lymphoblastic Leukemia (ALL)—Potential Role of Immune-Based Therapies. Current Hematologic Malignancy Reports, 2015, 10, 76-85.	2.3	7
133	Improving access to novel agents for childhood leukemia. Cancer, 2015, 121, 1927-1936.	4.1	5
134	Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , .	0.6	7
135	Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches. Trends in Pharmacological Sciences, 2015, 36, 645-660.	8.7	84
136	CD22ΔE12 as a molecular target for corrective repair using RNA <i>trans</i> -splicing: anti-leukemic activity of a rationally designed RNA <i>trans</i> -splicing molecule. Integrative Biology (United) Tj ETQq1 1 0.784	43 <b>1</b> 43 rgBT	/Oværlock 10

#	Article	IF	CITATIONS
137	Development and Integration of Antibody–Drug Conjugate in Non-Hodgkin Lymphoma. Current Oncology Reports, 2015, 17, 41.	4.0	31
138	Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia. Future Oncology, 2015, 11, 1729-1739.	2.4	10
139	Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 89-128.	0.1	0
140	Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 116-123.	1.7	9
141	Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opinion on Biological Therapy, 2015, 15, 601-611.	3.1	10
142	Prognostic Factors in Adolescent and Adult Patients With Acute Lymphoblastic Leukemia With Two Protocols of Chemotherapy: AÂCross-Sectional Study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e7-e14.	0.4	9
143	Antibodyâ€based therapies in Bâ€cell lineage acute lymphoblastic leukaemia. European Journal of Haematology, 2015, 94, 99-108.	2.2	26
145	Current status of antibody therapy in <scp>ALL</scp> . British Journal of Haematology, 2015, 168, 471-480.	2.5	38
146	Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Advances, 2016, 1, 260-264.	5.2	8
147	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Advances, 2016, 1, 250-259.	5.2	142
148	Adverse Events in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL): A Literature Review of Recent Clinical Trials. Journal of Leukemia (Los Angeles, Calif ), 2016, 04, .	0.1	1
149	Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. Molecular Medicine, 2016, 22, 632-642.	4.4	25
150	Immunotherapy for B acute lymphoblastic leukemia. Hematologie, 2016, 22, 39-48.	0.0	0
151	Linkers Having a Crucial Role in Antibody–Drug Conjugates. International Journal of Molecular Sciences, 2016, 17, 561.	4.1	187
152	Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?. Current Cancer Therapy Reviews, 2016, 12, 54-65.	0.3	3
153	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marcow Transplantation. Cancer 2016, 122, 2941, 2951	4.1	140
154	Final results of a single institution experience with a pediatricâ€based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper VAD regimen. American Journal of Hematology, 2016, 91, 819-823.	4.1	102
155	A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan. Experimental Animals, 2016, 65, 345-351.	1.1	10

#	Article	IF	CITATIONS
156	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica, 2016, 101, 1524-1533.	3.5	154
157	Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 2109-2118.	1.3	28
158	Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults. Current Oncology Reports, 2016, 18, 39.	4.0	38
159	A prospective study of sexual and urinary function before and after total mesorectal excision. International Journal of Colorectal Disease, 2016, 31, 1125-1130.	2.2	30
160	Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v69-v82.	1.2	268
161	Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2016, 11, 253-264.	2.3	17
162	Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design. Clinical Cancer Research, 2016, 22, 4913-4922.	7.0	8
163	Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer Journal, 2016, 6, e473-e473.	6.2	101
164	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 4381-4389.	1.6	478
165	Antibody-drug conjugates: Current status and future perspectives. , 2016, 167, 48-59.		51
166	New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leukemia Research, 2016, 49, 13-21.	0.8	29
167	Treating adults with acute lymphocytic leukemia: new pharmacotherapy options. Expert Opinion on Pharmacotherapy, 2016, 17, 2319-2330.	1.8	7
168	Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proceedings, 2016, 91, 1645-1666.	3.0	158
169	Antibody–drug conjugates for cancer therapy. Lancet Oncology, The, 2016, 17, e254-e262.	10.7	439
170	The functional results of radical rectal cancer surgery: review of the literature. Acta Chirurgica Belgica, 2016, 116, 1-10.	0.4	49
171	Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy, 2016, 8, 135-143.	2.0	17
172	Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Review of Hematology, 2016, 9, 329-334.	2.2	18
173	Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. Leukemia Research, 2016, 41, 12-20.	0.8	41

#	Article	IF	CITATIONS
174	Clinical updates in adult acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology, 2016, 99, 189-199.	4.4	30
175	Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia. Expert Review of Anticancer Therapy, 2016, 16, 159-164.	2.4	9
176	Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia. Immunology Letters, 2016, 172, 113-123.	2.5	16
177	The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies. Current Hematologic Malignancy Reports, 2016, 11, 165-174.	2.3	5
178	Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 96-103.	0.4	1
179	Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future. Expert Opinion on Therapeutic Targets, 2016, 20, 859-867.	3.4	15
180	Inotuzumab ozogamicin in relapsed Bâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2017, 98, 425-434.	2.2	41
181	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	27.0	1,443
182	Childhood Acute Lymphoblastic Leukemia. , 2017, , .		2
183	Chemotherapy for Leukemia. , 2017, , .		2
183 184	Chemotherapy for Leukemia. , 2017, , . Novel therapy for childhood acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1081-1099.	1.8	2
183 184 185	Chemotherapy for Leukemia., 2017, , .         Novel therapy for childhood acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1081-1099.         Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Advances in Therapy, 2017, 34, 1015-1035.	1.8	2 24 227
183 184 185 186	Chemotherapy for Leukemia., 2017, ,.         Novel therapy for childhood acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1081-1099.         Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Advances in Therapy, 2017, 34, 1015-1035.         Prophylactic transanal irrigation for low anterior resection syndrome following rectal resection.         Coloproctology, 2017, 39, 341-343.	1.8 2.9 0.3	2 24 227 1
183 184 185 186 187	Chemotherapy for Leukemia. , 2017, , .         Novel therapy for childhood acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1081-1099.         Antibodyâ€ <sup>c</sup> Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Advances in therapy, 2017, 34, 1015-1035.         Prophylactic transanal irrigation for low anterior resection syndrome following rectal resection. Coloproctology, 2017, 39, 341-343.         Inotuzumab Ozogamicin: First Global Approval. Drugs, 2017, 77, 1603-1610.	1.8 2.9 0.3 10.9	2 24 227 1
183 184 185 186 187	Chemotherapy for Leukemia., 2017, , .Novel therapy for childhood acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1081-1099.Antibodyâć "Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Advances in Therapy, 2017, 34, 1015-1035.Prophylactic transanal irrigation for low anterior resection syndrome following rectal resection. Coloproctology, 2017, 39, 341-343.Inotuzumab Ozogamicin: First Global Approval. Drugs, 2017, 77, 1603-1610.Treatment of Adult Acute Lymphocytic Leukemia (ALL) in 2017. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S57-S60.	1.8 2.9 0.3 10.9 0.4	2 24 227 1 145
183 184 185 186 187 188	Chemotherapy for Leukemia., 2017, , .         Novel therapy for childhood acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1081-1099.         AntibodyãC"Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Advances in Therapy, 2017, 34, 1015-1035.         Prophylactic transanal irrigation for low anterior resection syndrome following rectal resection. Coloproctology, 2017, 39, 341-343.         Inotuzumab Ozogamicin: First Global Approval. Drugs, 2017, 77, 1603-1610.         Treatment of Adult Acute Lymphocytic Leukemia (ALL) in 2017. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S57-S60.         Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncology, 2017, 13, 2233-2242.	1.8 2.9 0.3 10.9 0.4 2.4	2 24 227 1 145 0
<ul> <li>183</li> <li>184</li> <li>185</li> <li>186</li> <li>187</li> <li>188</li> <li>189</li> <li>189</li> </ul>	Chemotherapy for Leukemia. , 2017, , .         Novel therapy for childhood acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1081-1099.         AntibodyâC"Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Advances in Therapy, 2017, 34, 1015-1035.         Prophylactic transanal irrigation for low anterior resection syndrome following rectal resection. Coloproctology, 2017, 39, 341-343.         Inotuzumab Ozogamicin: First Global Approval. Drugs, 2017, 77, 1603-1610.         Treatment of Adult Acute Lymphocytic Leukemia (ALL) in 2017. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S57-S60.         Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncology, 2017, 13, 2233-2242.         How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?. Best Practice and Research in Clinical Haematology, 2017, 30, 261-274.	1.8 2.9 0.3 10.9 0.4 2.4 1.7	2 24 227 1 145 0 15

		15	Cizizzione
Ŧ		IF	CHATIONS
193	review and meta-analysis. Techniques in Coloproctology, 2017, 21, 929-936.	1.8	16
194	Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. Expert Opinion on Biological Therapy, 2017, 17, 1557-1564.	3.1	10
195	New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. Expert Review of Anticancer Therapy, 2017, 17, 725-736.	2.4	34
196	Immunotherapy in adult acute leukemia. Leukemia Research, 2017, 60, 63-73.	0.8	16
197	Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal, 2017, 7, e577.	6.2	757
198	Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Expert Review of Hematology, 2017, 10, 783-799.	2.2	7
200	Emerging biological therapies to treat acute lymphoblastic leukemia. Expert Opinion on Emerging Drugs, 2017, 22, 107-121.	2.4	18
201	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biology of Blood and Marrow Transplantation, 2017, 23, 285-292.	2.0	24
202	Manometric evaluation of anorectal function in patients treated with neoadjuvant chemoradiotherapy and total mesorectal excision for rectal cancer. Digestive and Liver Disease, 2017, 49, 91-97.	0.9	15
203	Prognostic impact of pretreatment cytogenetics in adult <scp>P</scp> hiladelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer, 2017, 123, 459-467.	4.1	49
204	Hematopoietic cell transplants for BCR/ABL negative acute lymphocytic leukemia. , 0, , 298-308.		0
205	Hematopoietic cell transplants for BCR/ABL positive acute lymphocytic leukemia. , 0, , 309-315.		0
206	Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Advances, 2017, 1, 1167-1180.	5.2	103
207	Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2017, 2017, 259-264.	2.5	1
208	Progress in adult ALL: incorporation of new agents to frontline treatment. Hematology American Society of Hematology Education Program, 2017, 2017, 28-36.	2.5	15
209	Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates. Drug Design, Development and Therapy, 2017, Volume 11, 2265-2276.	4.3	80
210	Hematopoietic cell transplants for children with acute lymphoblastic leukemia. , 0, , 291-297.		0
211	CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia. Journal of Clinical & Cellular Immunology, 2017, 08, .	1.5	0

#	Article	IF	CITATIONS
212	Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 361-367.	0.4	12
213	Update in Pediatric Oncology: Section A-New Developments in the Treatment of Pediatric Acute Lymphoblastic Leukemia. , 2018, , 461-483.		0
215	"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questionsâ€â€"Treatment of ALL. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 301-310.	0.4	6
216	Does previous transanal excision for early rectal cancer impair surgical outcomes and pathologic findings of completion total mesorectal excision? Results of a systematic review of the literature. Journal of Visceral Surgery, 2018, 155, 445-452.	0.8	16
218	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INOâ€VATE. Cancer, 2018, 124, 1722-1732.	4.1	43
219	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 240-248.	10.7	192
220	5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1867-E1875.	7.1	12
221	Treatment of Older Patients with Acute Lymphoblastic Leukaemia. Drugs and Aging, 2018, 35, 11-26.	2.7	14
222	Monoclonal Antibodies Targeting Hematological Malignancies. , 2018, , 79-116.		0
223	Treatment possibilities for low anterior resection syndrome: a review of the literature. International Journal of Colorectal Disease, 2018, 33, 251-260.	2.2	75
224	Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. Targeted Oncology, 2018, 13, 287-308.	3.6	12
225	Advances in adult acute lymphoblastic leukemia therapy. Leukemia and Lymphoma, 2018, 59, 1033-1050.	1.3	58
226	The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia. Annals of Pharmacotherapy, 2018, 52, 268-276.	1.9	5
227	Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia. Current Medical Research and Opinion, 2018, 34, 435-440.	1.9	22
228	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 230.	7.1	124
229	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
230	Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2018, 9, 347-356.	2.5	0
231	Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 574-578.	3.8	17

#	Article	IF	CITATIONS
232	An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2018, 7, IJH06.	1.6	3
233	Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. BMC Cancer, 2018, 18, 1117.	2.6	16
234	Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia. European Journal of Internal Medicine, 2018, 58, 22-27.	2.2	3
235	Should immunologic strategies be incorporated into frontline ALL therapy?. Best Practice and Research in Clinical Haematology, 2018, 31, 367-372.	1.7	2
236	Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 2018, Volume 8, 47-61.	2.7	21
237	Chemoimmunotherapy with inotuzumab ozogamicin combined with miniâ€hyper VD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage. Cancer, 2018, 124, 4044-4055.	4.1	88
238	Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies. Current Hematologic Malignancy Reports, 2018, 13, 555-569.	2.3	6
239	Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. Chemotherapy, 2018, 63, 220-224.	1.6	19
240	Le syndrome de résection antérieure du rectum. Quels messages délivrer aux praticiens et aux patients en 2018�. Journal De Chirurgie Viscérale, 2018, 155, 390-399.	0.0	0
241	Overstaging: A Challenge in Rectal Cancer Treatment. Visceral Medicine, 2018, 34, 301-306.	1.3	16
242	CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?. Expert Opinion on Orphan Drugs, 2018, 6, 563-566.	0.8	4
243	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematology American Society of Hematology Education Program, 2018, 2018, 25-34.	2.5	29
244	Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2018, 2018, 9-15.	2.5	22
245	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Advances, 2018, 2, 3393-3403.	5.2	41
246	Prevention and treatment of relapse after stem cell transplantation with immunotherapy. Bone Marrow Transplantation, 2018, 53, 664-672.	2.4	11
247	Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatric Drugs, 2018, 20, 395-408.	3.1	76
248	Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. Journal of Blood Medicine, 2018, Volume 9, 67-74.	1.7	18
249	Acute Lymphoblastic Leukemia in Adults. , 2018, , 1029-1054.e2.		2

#	Article	IF	CITATIONS
250	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2018, 11, 99.	17.0	35
251	Novel Therapies in Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 289-299.	2.3	41
252	Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. Frontiers in Immunology, 2018, 9, 239.	4.8	35
253	Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. Toxins, 2018, 10, 32.	3.4	19
254	Prevalence of low anterior resection syndrome at a regional Australian centre. ANZ Journal of Surgery, 2018, 88, E813-E817.	0.7	15
255	Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Drug Design, Development and Therapy, 2018, Volume 12, 2293-2300.	4.3	45
256	Anterior resection syndrome: What should we tell practitioners and patients in 2018?. Journal of Visceral Surgery, 2018, 155, 383-391.	0.8	25
257	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 2018, 24, 20-28.	30.7	1,030
258	Ultralow Anterior Resection and Coloanal Anastomosis for Low-Lying Rectal Cancer: An Appraisal Based on Bowel Function. Digestive Surgery, 2019, 36, 409-417.	1.2	21
259	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Annals of Hematology, 2019, 98, 2389-2398.	1.8	24
260	Approach to the Adult Acute Lymphoblastic Leukemia Patient. Journal of Clinical Medicine, 2019, 8, 1175.	2.4	28
261	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 471-479.	0.4	2
262	Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia. Medicina ClÃnica (English Edition), 2019, 153, 28-34.	0.2	1
263	Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews, 2019, 71, 671-697.	16.0	13
264	Recent advances on blinatumomab for acute lymphoblastic leukemia. Experimental Hematology and Oncology, 2019, 8, 28.	5.0	31
265	Hematological malignancies and molecular targeting therapy. European Journal of Pharmacology, 2019, 862, 172641.	3.5	44
266	B-cell depleting immunotherapies: therapeutic opportunities and toxicities. Expert Review of Clinical Immunology, 2019, 15, 497-509.	3.0	3
267	Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2019, 10, 204062071984949.	2.5	18

#	Article	IF	CITATIONS
268	Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1498-1504.	2.0	49
269	Perspectives on the Use of a Medium-Dose Etoposide, Cyclophosphamide, and Total Body Irradiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation: The Japanese Experience from 1993 to Present. Journal of Clinical Medicine, 2019, 8, 569.	2.4	6
270	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 1720-1729.	2.0	53
271	Inotuzumab ozogamicin in combination with lowâ€intensity chemotherapy (miniâ€HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019. 125. 2579-2586.	4.1	63
272	Poor Penetration of Existing Effective Chemoimmunotherapy for the Treatment of Older Patients With Newly Diagnosed Acute Lymphocytic Leukemia (ALL) or Refractory/Relapsed ALL. Journal of Oncology Practice, 2019, 15, 77-79.	2.5	2
273	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomarker Research, 2019, 7, 9.	6.8	19
274	Antibody-Drug Conjugate-Based Therapeutics: State of the Science. Journal of the National Cancer Institute, 2019, 111, 538-549.	6.3	257
275	Effect of Stem Cell Transplant on Survival in Adult Patients With Acute Lymphoblastic Leukemia: NCDB Analysis. Anticancer Research, 2019, 39, 1899-1906.	1.1	8
276	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. Journal of Hematology and Oncology, 2019, 12, 17.	17.0	80
277	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2019, 12, 15.	17.0	38
279	Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Advances, 2019, 3, 96-104.	5.2	37
280	Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer and Metastasis Reviews, 2019, 38, 595-610.	5.9	65
281	Posttransplant maintenance therapy for acute leukemias. Current Opinion in Hematology, 2019, 26, 96-111.	2.5	2
283	Recent Progress in Linker Technology for Antibody-Drug Conjugates: Methods for Connection and Release. , 2019, , 93-123.		2
284	Use of inotuzumabâ€ozogamicin in a child with Down syndrome and refractory Bâ€cell precursor acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27562.	1.5	5
285	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology, 2019, 94, 408-416.	4.1	11
286	Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Human Vaccines and Immunotherapeutics, 2019, 15, 594-602.	3.3	23
287	Increased survival due to lower toxicity for highâ€risk Tâ€cell acute lymphoblastic leukemia patients in two consecutive pediatricâ€inspired PETHEMA trials. European Journal of Haematology, 2019, 102, 79-86.	2.2	14

#	Article	IF	CITATIONS
288	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2019, 33, 884-892.	7.2	158
289	New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances. Hematological Oncology, 2020, 38, 22-33.	1.7	7
290	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematology,the, 2020, 7, e61-e72.	4.6	56
291	Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer, 2020, 126, 1152-1160.	4.1	29
292	Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. Expert Review of Anticancer Therapy, 2020, 20, 879-891.	2.4	2
293	Randomized clinical trial comparing side to end vs end to end techniques for colorectal anastomosis. International Journal of Surgery, 2020, 83, 220-229.	2.7	15
294	Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine, 2020, 56, 102821.	6.1	103
295	Long-term bowel dysfunction following low anterior resection. Scientific Reports, 2020, 10, 11882.	3.3	32
296	Monoclonal antibodies in frontline acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2020, 33, 101226.	1.7	3
297	Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2020, 33, 101225.	1.7	6
298	Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy. Blood and Lymphatic Cancer: Targets and Therapy, 2020, Volume 10, 7-20.	2.7	14
299	Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 713-719.	0.4	9
300	BCMA-targeted immunotherapy for multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 125.	17.0	108
301	Recent Advances in Managing Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 330-342.	3.8	40
302	Using Pharmacology to Squeeze the Life Out of Childhood Leukemia, and Potential Strategies to Achieve Breakthroughs in Medulloblastoma Treatment. Pharmacological Reviews, 2020, 72, 668-691.	16.0	6
303	Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e724-e733.	0.4	7
304	Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062072092757.	2.5	13
305	Five-year single center experience of sacral neuromodulation for isolated fecal incontinence or fecal incontinence combined with low anterior resection syndrome. Techniques in Coloproctology, 2020, 24, 947-958.	1.8	16

#	Article	IF	CITATIONS
306	Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system. European Journal of Health Economics, 2020, 21, 1105-1116.	2.8	3
307	Advances in Supportive Care for Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 276-293.	2.3	8
308	Should the rectal defect be sutured following TEMS/TAMIS carried out for neoplastic rectal lesions? A meta-analysis. Annals of the Royal College of Surgeons of England, 2020, 102, 647-653.	0.6	8
309	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer, 2020, 126, 1837-1855.	4.1	20
310	Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062071989989.	2.5	31
311	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugatesÂand bispecific T-cell engagers. European Journal of Cancer, 2020, 128, 107-118.	2.8	36
312	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 556-560.e2.	0.4	12
313	Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e132-e143.	3.8	15
314	Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. Journal of Controlled Release, 2021, 329, 676-695.	9.9	111
315	Low anterior resection syndrome following different surgical approaches for low rectal endometriosis: A retrospective multicenter study. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 860-867.	2.8	23
316	Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models. Molecular Cancer Therapeutics, 2021, 20, 320-328.	4.1	17
317	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia. Cancer, 2021, 127, 905-913.	4.1	30
318	Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory Bâ€acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28718.	1.5	30
319	Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2. Blood Advances, 2021, 5, 584-592.	5.2	7
320	The clinical development of antibody–drug conjugates — lessons from leukaemia. Nature Reviews Clinical Oncology, 2021, 18, 418-433.	27.6	28
321	Unintended Regulatory Caused Early Death—A Difficult Endpoint in Cancer Patient Care and Treatment. Cancers, 2021, 13, 1457.	3.7	2
322	Longâ€ŧerm followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038.	4.1	24
323	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies, Journal of Fungi (Basel, Switzerland), 2021, 7, 186.	3.5	18

#	Article	IF	CITATIONS
324	Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments. International Journal of Molecular Sciences, 2021, 22, 5774.	4.1	23
326	Polymeric nanomedicines targeting hematological malignancies. Journal of Controlled Release, 2021, 337, 571-588.	9.9	15
327	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1079-1109.	4.9	96
328	Natural Product Cytotoxins as Payloads for Antibody Drug Conjugates. , 2013, , 97-119.		3
329	Emerging Molecular Therapies for the Treatment of Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 2013, 779, 341-358.	1.6	2
330	Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 117-131.	0.6	1
331	LeukÃ <b>m</b> ien und Lymphome. , 2018, , 267-357.		1
332	Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 294-304.	2.3	17
333	Navigating the nexus of MRD and novel agents in ALL. Hematology American Society of Hematology Education Program, 2019, 2019, 9-16.	2.5	2
334	Moving immunotherapy into the front line in ALL. Hematology American Society of Hematology Education Program, 2019, 2019, 209-217.	2.5	13
335	Monoclonal Antibody-Based Therapies in the Treatment of Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 294-299.	3.8	8
336	Antibody-Drug Conjugates in Hematologic Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e108-e113.	3.8	3
337	A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer. Oncotarget, 2016, 7, 71536-71547.	1.8	7
338	Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomolecules and Therapeutics, 2015, 23, 493-509.	2.4	128
339	Monoclonal antibody therapy of adult acute lymphoblastic leukemia: progress and challenge for new clinical trials. Drugs and Cell Therapies in Hematology, 2013, 2, 5.	0.1	1
340	The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin. Annali Dell'Istituto Superiore Di Sanita, 2013, 49, 150-68.	0.4	17
341	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 81-112.	4.9	102
342	Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia. Drugs in Context, 2020, 9, 1-15.	2.2	5

#	Article	IF	CITATIONS
343	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Advances, 2022, 6, 1742-1753.	5.2	33
344	Targeted Toxins in Cancer Immunotherapy. , 2013, , 377-396.		0
346	Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 165-183.	0.1	0
347	MRD evaluation, targeted therapy and stem cell transplantation: how to combine in adult ALL. Cellular Therapy and Transplantation, 2015, 4, 19-23.	0.3	0
348	Immunotherapy for B-acute Lymphoblastic Leukemia by Focusing on Monoclonal Antibody and CAR- T-cell Application. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2016, 26, 227-238.	0.1	0
349	Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. , 2017, , 201-237.		0
350	Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results. , 2017, , 123-136.		0
351	Antibody Based Therapies in Acute Leukemia. Current Drug Targets, 2017, 18, 257-270.	2.1	3
352	Akute lymphatische Leukänie des äeren Patienten. , 2017, , 1-11.		0
353	Blinatumomab for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results. , 2017, , 137-149.		0
354	Akute lymphatische Leukänie des äeren Patienten. , 2018, , 229-239.		0
355	Comparison of Pelvic Autonomic Nerve Function Recovery Between the Group only with Surgery and Group with Additional Acupuncture and Electrotherapy for Treatment in Patients with Rectal Cancer after Anus-Preserving Operation. Acupuncture and Electro-Therapeutics Research, 2018, 43, 103-118.	0.2	1
356	El trasplante alogénico de progenitores hematopoyéticos en la era de las nuevas terapias en la leucemia linfoblA¡stica aguda. Medicina ClÃnica, 2019, 153, 28-34.	0.6	2
357	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. Cancers, 2021, 13, 5418.	3.7	7
358	The value of immunotherapy in pediatric leukemia and lymphoma. Memo - Magazine of European Medical Oncology, 2021, 14, 397-401.	0.5	2
359	Immuno-Target Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia. Korean Journal of Medicine, 2020, 95, 320-324.	0.3	0
360	Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1993-2011. International Journal of Hematology-Oncology and Stem Cell Research, 2017, 11, 58-62.	0.3	1
361	Vascular Disorders of the Liver. , 2022, , 931-951.		0

#	Article	IF	CITATIONS
362	Monoclonal Antibody-Based Treatment and Other New Agents for B-Lineage Acute Lymphoblastic Leukemia. , 2022, , 295-328.		2
363	Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects. Pharmacology, 2022, 107, 368-375.	2.2	4
364	Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!. JCO Oncology Practice, 2022, 18, 479-487.	2.9	17
365	Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML). Annali Dell'Istituto Superiore Di Sanita, 2013, 49, 190-208.	0.4	9
366	CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Advances, 2023, 7, 251-255.	5.2	4
367	Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review. Human Antibodies, 2022, , 1-14.	1.5	0
368	A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). International Journal of Hematology, 0, , .	1.6	1
369	Synthesis and biological properties of maleimide-based macrocyclic lactone enediynes. Organic and Biomolecular Chemistry, 2022, 20, 5481-5488.	2.8	2
370	CAR T cell therapy in advanced Bâ $\in$ ALL with heavy disease burden. Immunomedicine, 0, , .	0.7	0
371	Quantitation and Identification of Therapeutic Anti-CD22 Monoclonal Antibodies in a Cell-Based ELISA Method. Antibodies, 2022, 11, 53.	2.5	Ο
372	The use of multistage immunotherapy to achieve remission before haploidentical hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia and the treatment of complications of this therapy in the early post-transplant period: a review of the literature and a clinical case. Russian Journal of Pediatric Hematology and Oncology, 2022, 9, 85-92.	0.3	0
373	Miniâ€hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric Bâ€acute lymphoblastic leukemia. Pediatric Blood and Cancer, 0, , .	1.5	3
374	New therapeutic modalities in the treatment of childhood acute lymphoblastic leukemia. Cesko-Slovenska Pediatrie, 2022, 77, 265-271.	0.2	0
376	When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)?. Best Practice and Research in Clinical Haematology, 2022, 35, 101404.	1.7	Ο
377	Immunotherapy approaches for hematological cancers. IScience, 2022, 25, 105326.	4.1	9
378	Current Management of Adult Acute Lymphoblastic Leukaemia: Emerging Insights and Outstanding Questions. European Medical Journal Hematology, 0, , 117-128.	0.0	1
379	Recent progress in pediatric lymphoblastic leukemia. International Journal of Hematology, 0, , .	1.6	0
380	Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?. International Journal of Molecular Sciences, 2023, 24, 1045.	4.1	2

CITATION REPORT ARTICLE IF CITATIONS Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges 2.0 1 and Future Directions. OncoTargets and Therapy, 0, Volume 16, 1-16. Infectious complications during monoclonal antibodies treatments and cell therapies in Acute 3.6 Lymphoblastic Leukemia. Clinical and Experimental Medicine, 0, , . Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. 5.7 2 Blood Reviews, 2023, 59, 101042. Sequencing <scp>antigenâ€targeting</scp> antibodies and cellular therapies in adults with relapsed/refractory <scp>Bâ€cell</scp> acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, 666-680. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four 17.0 18 decades. Journal of Hematology and Oncology, 2023, 16, . Immunotherapy for Acute Leukemia., 2022, , 1-41. Management of B-cell lineage acute lymphoblastic leukemia: expert opinion from an Indian panel via 2.8 2 Delphi consensus method. Frontiers in Oncology, 0, 13, . Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2023, 16, . Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic 1.7 2 leukemia: a prospective phase II study. Korean Journal of Internal Medicine, 2023, 38, 734-746. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or 2.2 refractory acute lymphoblastic leukemia in Spain. European Journal of Haematology, 0, , . Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute 3.2 1 Lymphoblastic Leukemia. Biomedicines, 2023, 11, 1886. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and 4.8 practical considerations. Frontiers in Immunology, 0, 14, . Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal 17.1 5 Transduction and Targeted Therapy, 2023, 8, . New monoclonal antibodies for the treatment of acute lymphoblastic leukemia., 2024, , 165-192.

396	Treatmentâ€related adverse events of antibodyâ€drug conjugates in clinical trials: A systematic review and metaâ€analysis. , 2023, 2, 346-375.		0	
397	Structure and Signalling Function of the B-Cell Antigen Receptor and Its Coreceptors. , 2024, , 93-128.		0	
398	New Developments in the Treatment of Pediatric Acute Lymphoblastic Leukemia. , 2023, , 605-628.		0	
399	Safety and longâ€ŧerm survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A singleâ€center phase 1,2 trial. American Journal of	4.1	0	

Hematology, 2024, 99, 836-843.

381

383

384

385

387

388

389

391

393

#	Article	IF	CITATIONS
400	Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults. Critical Reviews in Oncology/Hematology, 2024, 196, 104317.	4.4	0
401	Lymphangiogenesis and Stem Cells in Hematological Malignancies. , 2024, , .		0